Links
Archives
Saturday, March 25, 2006
Quadramet and related articles
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6895-900.
Osteoblastic metastases and osteosarcoma can avidly concentrate bone-seeking radiopharmaceuticals. We sought to increase effectiveness of high-dose (153)Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine. Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153Sm-EDTMP. Gemcitabine was administered 1 day after samarium infusion. Residual total body radioactivity was within the safe range of <3.6 mCi on day +14 (1.1 +/- 0.4 mCi; range, 0.67-1.8 mCi).
Quadramet (153-samarium lexidronam) is a bone-seeking agent of which high dose can be
safely administered. However, Dow chemicals,which licenced Cytogen, offered a newer radiopharmaceutical for bone marrow ablation. Since the newer radiopharmaceuticals, STR (166-holmium DOTMP), requires more dose than 153-semarium, Cytogen refused the offer and Dow chemical dit not licenses Cytogen for using Quadramet.
J Natl Cancer Inst. 2004 Nov 3;96(21):1573-4.
Osteoblastic metastases and osteosarcoma can avidly concentrate bone-seeking radiopharmaceuticals. We sought to increase effectiveness of high-dose (153)Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine. Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153Sm-EDTMP. Gemcitabine was administered 1 day after samarium infusion. Residual total body radioactivity was within the safe range of <3.6 mCi on day +14 (1.1 +/- 0.4 mCi; range, 0.67-1.8 mCi).
Quadramet (153-samarium lexidronam) is a bone-seeking agent of which high dose can be
safely administered. However, Dow chemicals,which licenced Cytogen, offered a newer radiopharmaceutical for bone marrow ablation. Since the newer radiopharmaceuticals, STR (166-holmium DOTMP), requires more dose than 153-semarium, Cytogen refused the offer and Dow chemical dit not licenses Cytogen for using Quadramet.
J Natl Cancer Inst. 2004 Nov 3;96(21):1573-4.
